
    
      The duration of the study period for each participant was approximately 22 weeks; including
      up to 4 weeks screening period, 12-week double-blind treatment period and 6-week safety
      follow-up period.

      Participants who completed the 12-week treatment period were offered enrollment in a separate
      long-term extension study (LTS11210/NCT01146652).
    
  